Vertex stock popped Tuesday — while shares of rival Maze Therapeutics skyrocketed — on a surprise expansion for their kidney disease drugs. The post The Surprise That Sent Vertex — And Its Chief Rival — Soaring appeared first on Investor's Business Daily .
Maze Therapeutics, Inc. Common Stock (MAZE) News
Latest headlines that mention MAZE, newest first · each headline opens the original publisher
- Last price
- $25.88
- Day change
- -1.41%
- Next earnings
- 2026-11-05
MAZE headlines
latest coverageThe executive liquidated his entire direct holdings as the stock plunged about 50% from its 52-week high.
This clinical-stage biotech targeting kidney and metabolic diseases reported a notable insider sale, recent filings show.
This clinical-stage biotech advancing precision medicines reported a notable insider sale amid strong one-year share performance.
Maze Therapeutics is a U.S. biotech advancing clinical-stage precision medicines for renal and metabolic diseases.
This clinical-stage biotech focused on precision medicines for renal and metabolic diseases just reported a notable insider sale.
Also mentioned with MAZE
30dHeadlines that tag both tickers
MAZE news alerts
Get an alert by email or push when a new headline mentions MAZE.
More news
News headlines aggregated from third-party publishers via public RSS feeds and tagged with the tickers they mention. Frenzy Capital does not publish or endorse the content; clicking a headline opens the original publisher in a new tab.